buy

Esperion Therapeutis.Inc. buy Needham & Company LLC

Esperion Therapeutis.Inc.

Start price

€1.55

/ 50%

Target price

02.08.24

Performance (%)

Price

Summary

This prediction is currently active. With a performance of the BUY prediction by Needham___Company_LL is a big success. This prediction currently runs until 02.08.24. The prediction end date can be changed by Needham___Company_LL at any time. Needham___Company_LL has 50% into this prediction

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.

Feedback

Performance without dividends (%)

Name	1w	1m
Esperion Therapeutis.Inc.
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by Needham___Company_LL for this prediction

In the thread Esperion Therapeutis.Inc. diskutieren

Prediction Buy

Perf. (%)

Target price 8.227

Change

Ends at

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its price target lowered by analysts at Needham & Company LLC from $10.00 to $9.00. They now have a "buy" rating on the stock.

Ratings data for ESPR provided by MarketBeat

Needham & Company LLC